344940-70-1

Usage

Uses

Used in Pharmaceutical Industry:
2-Amino-5-bromo-3-phenylpyrazine is used as a building block for the synthesis of new drug molecules. It has potential applications in medicinal chemistry, particularly for creating new drugs with potential anti-cancer, anti-inflammatory, or antimicrobial properties.
Used in Agrochemical Research:
2-Amino-5-bromo-3-phenylpyrazine is used as an intermediate in the synthesis of agrochemicals, contributing to the development of new pesticides and other agricultural chemicals.
Used in Dye Synthesis:
2-Amino-5-bromo-3-phenylpyrazine is also used as an intermediate in the synthesis of dyes, playing a role in the creation of various colorants for different industries.

Upstream product

• 24241-18-7 2-amino-3,5-dibromopyrazine 
• 98-80-6 phenylboronic acid 
• 41270-67-1 2-Amino-3-phenylpyrazine 
• 960-16-7 tributylphenylstannane 

Downstream Products

• 625848-40-0 5-(4-[tert-butyl(dimethyl)silyloxy]phenyl)-3-phenyl-2-pyrazinamine 
• 1202278-29-2 tert-butyl 5-(5-amino-6-phenylpyrazin-2-yl)thiazol-2-yl(isopropyl)carbamate 
• 1202278-30-5 tert-butyl isopropyl(5-(8-phenylimidazo[1,2-a]pyrazin-6-yl)thiazol-5-yl)carbamate 
• 1202277-75-5 N-isopropyl-5-(8-phenylimidazo[1,2-a]pyrazin-6-yl)thiazol-2-amine 
• 41270-70-6 2-amino-3,5-diphenylpyrazine 

Relevant academic research and scientific papers

Heterocyclic Adenosine Receptor Antagonists

Heterocyclic compounds useful as antagonists of adenosine receptors, and methods of treatment of diseases using antagonists of adenosine receptors are disclosed herein. Also disclosed herein are pharmaceutical compositions and methods of administration of

ATP-INDEPENDENT BIOLUMINESCENT REPORTER VARIANTS TO IMPROVE IN VIVO IMAGING

Provided herein are chemically modified luciferase substrates for spectrally shifted emission and enhanced water solubility. Provided herein are engineered luciferases. Moreover, provided herein are new ATP-independent bioluminescent reporters which have improved biochemical and photophysical properties and are expected to have broad applications. Finally, provided herein are spectral-resolved triple-color bioluminescent systems, suitable for flexible and convenient approaches to monitor multiple biological events in either qualitative or quantitative manners.

Selectfluor-promoted regioselective chlorination/bromination of 2-aminopyridines and 2-aminodiazines using LiCl/LiBr

Using LiCl as a chlorine source, the chlorination of 2-aminopyridines or 2-aminodiazines in the presence of Selectfluor and DMF is established under mild conditions. This method gives chlorinated pyridines or diazines in good to high yields with high regioselectivities. Also, this method is extended to the bromination of 2-aminopyridines or 2-aminodiazines by using LiBr. The regioselectivity of the chlorination reaction is strongly dependent upon the substituent pattern in either the 2-aminopyridines or 2-aminodiazines. The synthesis of Buparlisib from chlorinated pyridines was explored. A study of the mechanism revealed that this chlorination occurs via either a pyridine or diazine radical process.

TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF

The present invention is directed to six membered heteroaryl benzamide compounds of formula (I), which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.

TRIAZOLOPYRIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS

A compound of Formula (I) and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula (I), and methods of treating conditions associated with the activity of

IMIDAZOPYRIDINE AND IMIDAZOPYRAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS

A compound of Formula (I) or Formula (II) and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula (I) or Formula (II), and methods of treating conditions

Pyrazinecarboxamide derivatives as CB1 antagonists

The present invention relates to compounds of the formula I: wherein R1 to R8 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors, such as obesity.

Synthesis of 3,7-dihydroimidazo[1,2a]pyrazine-3-ones and their chemiluminescent properties

A series of 3,7-dihydroimidazo[1,2a]pyrazine-3-ones were prepared from 2-amino-3,5-dibromopyrazine. The concise synthesis of coelenterazine (5j), in three steps, 48% overall yield and >99% purity exemplifies the strategy. Further, the synthetic approach facilitated the regiospecific incorporation of carboxyalkyl linkers on the 3,7-dihydroimidazo[1,2a]pyrazine-3-one nucleus that are required for bioconjugation. Peroxymonocarbonate, an electrophilic oxidant, was used to initiate 'pseudo-flash' chemiluminescence from this class of molecules.

Chemi- and bioluminescence of coelenterazine analogues with a conjugated group at the C-8 position

The chemiliminescent compound coelenterazine is involved in various bioluminescence reactions as the substrates, causing the luminescence with an emission peak in the range of 450-475 nm. Anticipating the introduction of a bathochromicshift of the lumines